Invasive candidiasis in intensive care units in China: In vitro antifungal susceptibility in the China-SCAN study

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 1, 2014, Pages 162-167

  Liu, Wei ^a   Tan, Jingwen ^a   Sun, Jimei ^b   Xu, Zhijiang ^c   Li, Min ^d   Yang, Qing ^e   Shao, Haifeng ^f   Zhang, Liyan ^g   Liu, Weixia ^a   Wan, Zhe ^a   Cui, Wei ^c   Zang, Bin ^b   Jiang, Dongpo ^d   Fang, Qiang ^e   Qin, Bingyu ^h   Qin, Tiehe ^g   Li, Weiqin ^f   Guo, Fengmei ⁱ   Liu, Dawei ^j   Guan, Xiandong ^k   Yu, Kaijiang ^l   Qiu, Haibo ⁱ   Li, Ruoyu ^a   more..

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

^b CHINA MEDICAL UNIVERSITY   (China)

^c THE SECOND AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^d THIRD MILITARY MEDICAL UNIVERSITY   (China)

^e ZHEJIANG UNIVERSITY   (China)

^f JINLING HOSPITAL   (China)

^g GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^h HENAN PROVINCIAL PEOPLE'S HOSPITAL   (China)

ⁱ SOUTHEAST UNIVERSITY   (China)

^j PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^k SUN YAT SEN UNIVERSITY   (China)

^l HARBIN MEDICAL UNIVERSITY   (China)

more..

Author keywords

Albicans; Azoles; Candida; Non albicans; Resistance

Indexed keywords

AMPHOTERICIN B; CASPOFUNGIN; FLUCONAZOLE; ITRACONAZOLE; VORICONAZOLE;

ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BROTH DILUTION; CANDIDA ALBICANS; CANDIDA ERNOBII; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA NORVEGENSIS; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CHINA; CROSS RESISTANCE; DRUG DETERMINATION; HUMAN; IN VITRO STUDY; INTENSIVE CARE UNIT; INVASIVE CANDIDIASIS; MAJOR CLINICAL STUDY; NONHUMAN; PICHIA ANOMALA; PICHIA GUILLIERMONDII; YARROWIA LIPOLYTICA;

ALBICANS; AZOLES; CANDIDA; NON-ALBICANS; RESISTANCE;

ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS, INVASIVE; CHINA; HUMANS; INTENSIVE CARE UNITS; MICROBIAL SENSITIVITY TESTS; MYCOLOGICAL TYPING TECHNIQUES;

EID: 84890349673     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt330     Document Type: Article

References (20)

1. Bouza E, Munoz P. Epidemiology of candidemia in intensive care units. Int J Antimicrob Agents 2008; 32 Suppl 2: S87-91.
2. Horn DL, Neofytos D, Anaissie EJ et al. Epidemiology and outcome of candidemia in 2019 patients: data from the Prospective Antifungal Therapy Alliance registry. Clin Infect Dis 2009; 48: 1695-703.
3. Kett D, Azoulay E, Echeverria P et al. Candida bloodstream infections in intensive care units: analysis of the extended prevalence of infection in intensive care unit study. Crit Care Med 2011; 39: 665-70.
4. Diekema DJ, Messer SA, Brueggemann AB et al. Epidemiology of candidemia: 3-year results from the Emerging Infections and the Epidemiology of IowaOrganisms study. JClinMicrobiol 2002; 40: 1298-303.
5. Playford EG, Lipman J, Sorrell T. Management of invasive candidiasis in the intensive care unit. Drugs 2010; 70: 823-39.
6. Holley A, Dulhunty J, Blot S et al. Temporal trends, risk factors and outcomes in albicans and non-albicans candidaemia: an international epidemiological study in four multidisciplinary intensive care units. Int J Antimicrob Agents 2009; 33: 554.e1-7.
7. Yap HY, Kwok KM, Gomersall CD et al. Epidemiology and outcome of Candida bloodstream infection in an intensive care unit in Hong Kong. Hong Kong Med J 2009; 15: 255-61.
8. Li S, An Y. Retrospective analysis of invasive fungal infection in surgical intensive care unit. Natl Med J China 2010; 90: 382-5.
9. Pfaller MA, Diekema DJ, Gibbs DL et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion. J Clin Microbiol 2010; 48: 1366-77.
10. Guo F, Yang Y, Kang Yet al. Invasive candidiasis in intensive care units in China: a multicentre prospective observational study. J Antimicrob Chemother 2013; 68: 1660-8.
11. Kurtzman CP, Robnett CJ. Identification of clinically important ascomycetous yeasts based on nucleotide divergence in the 5' end of the large-subunit (26S) ribosomal DNA gene. J Clin Microbiol 1997; 35: 1216-23.
12. Lu HZ, Jia JH, WangQMet al. Candida asparagi sp. nov., Candida diospyri sp. nov. andCandida qinlingensis sp. nov., novelanamorphic, ascomycetous yeast species. Int J Syst Evol Microbiol 2004; 54: 1409-14.
13. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts-Third Edition: Approved Standard M27-A3. CLSI, Wayne, PA, USA, 2008.
14. Pfaller MA, Messer SA, Woosley LN et al. Echinocandin and triazole antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 2010 to 2011: application of new CLSI clinical breakpoints and epidemiological cutoffvalues for characterization of geographic and temporal trends of antifungal resistance. J Clin Microbiol 2013; 51: 2571-81.
15. Pfaller MA, Diekema DJ. Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012. J Clin Microbiol 2012; 50: 2846-56.
16. Xie GH, Fang XM, Fang Q et al. Impact of invasive fungal infection on outcomes of severe sepsis: a multicenter matched cohort study in critically ill surgical patients. Crit Care 2008; 12: R5.
17. Bassetti M, Ansaldi F, Nicolini L et al. Incidence of candidaemia and relationship with fluconazole use in an intensive care unit. J Antimicrob Chemother 2009; 64: 625-9.
18. Lockhart SR, Messer SA, Pfaller MA et al. Lodderomyces elongisporus masquerading as Candida parapsilosis as a cause of bloodstream infections. J Clin Microbiol 2008; 46: 374-6.
19. Pfaller MA, Boyken L, Hollis RJ et al. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J Clin Microbiol 2008; 46: 150-6.
20. Mills EJ, Perri D, Cooper Cet al. Antifungal treatment for invasive Candida infections:amixedtreatment comparisonmeta-analysis. AnnClin Microbiol Antimicrob 2009; 8: 23.